|
Psychotic
Disorders
Includes:
Schizophrenia,
Schizoaffective Disorder, Schizophreniform,
Psychosis (NOS)
Clinical
Research Psychotic Disorders
How
to use this page: The research studies
at UNC target the chronic
and early
stages of psychotic disorders. Below are
the names and brief descriptions of each
study. If you see a study that may apply
to you, click on the link and get further
details on the study and contact information.
| Chronic
Stages of Psychotic Disorders
|
|
| Adults
and adolescents with psychotic symptoms
persisting for 1 year or longer. |
| |
SWITCH
Study: Metabolic and weight effects
of a switch to aripiprazole
The
purpose of this 14 week study is to
determine if subjects who switch from
olanzpine, quetiapine or risperidone
to aripiprazole show changes in body
composition, weight, lipids, glucose,
(and other metabolic markers), energy
expenditure or caloric consumption.
Ages:
18-65 |
| |
MAPS:
Mapping of Brain Function in Schizophrenia
The purpose of this study is to use
magnetic resonance imaging (MRI) and
or electrophysiological recording (EEG)
to evaluate brain function, structure
and/or chemistry.
Ages:
9-60, length of symptoms or criteria:
diagnosed with schizophrenia or schizoaffective
disorder, and taking an atypical antipsychotic. |
| |
FBIRN: Biomedical Informatics Research Network
The
purpose of this study is the development
and validation of functional magnetic
resonance imaging (fMRI) protocols
for a large-scale multi-center study
of schizophrenia. We are looking
for individuals ages 18-70 who have
been diagnosed with schizophrenia
or schizoaffective disorder. Study
participation includes two 2 hour
MRI appointments one month apart.
The first appointment also includes
a two hour clinical assessment, for
a total visit time of four hours.
Women must be willing to provide
a blood sample for a pregnancy test
within 3 days of the MRI scan. Subjects
are compensated by the hour based
on the length of their visit. If
you would like more information, please
contact Carolyn Bellion at 919-966-9988.
Ages:
18-70 |
| |
CAMP: Clinical Management of Metabolic Problems in Patients with Schizophrenia: Switching to Aripiprazole versus Continued Treatment with Olanzapine, Quetiapine, or Risperidone
The purpose of this six-month study is to compare the effects of switching to aripiprazole versus continued treatment with olanzapine, quetiapine, or risperidone on the risk of cardiovascular disease.
Ages 18-65 |
| Early
Stages of Psychotic Disorders
|
|
|
| First
episode or early course is identified
in adults and adolescents who have transitioned
from a pre-psychotic state to the first
full-blown psychotic state. |
| |
MAPS:
Mapping of Brain Function in Schizophrenia
The purpose of this study is to use
magnetic resonance imaging (MRI) and
or electrophysiological recording (EEG)
to evaluate brain function, structure
and/or chemistry.
Ages:
9-60, length of symptoms or criteria:
diagnosed with schizophrenia or schizoaffective
disorder, and taking an atypical antipsychotic. |
| |
GRIP:
Randomized
Controlled Trial of the Graduated
Recovery Intervention Program for
Early Psychosis
The
purpose of this study is to implement
a new manual-based intervention for
early psychosis, the Graduated Recovery
Intervention Program (GRIP), in the
context of a small-scale randomized
controlled trial to evaluate its efficacy.
Ages:
18 and older
|
| |
| SAFE
Study: Amantadine for prevention of
weight gain in first episode psychosis
The purpose of this study is to determine
if amantadine added very soon after
starting olanzapine therapy can prevent
weight gain due to olanzapine, in
first episode subjects.
Ages: 18-45, all races and genders
|
| |
UNC
Schizophrenia Research Center
The UNC Silvio O. Conte Center for the
neuroscience of mental disorders is
conducting four interrelated studies
to identify critical brain events that
trigger the development of psychotic
symptoms associated with schizophrenia.
Age:
pre-natal to adult |
back
to top »
| Child
and Adolescent Disorders |
|
| Children
and adolescents with psychotic symptoms. |
| IMPACT-
IMPROVING METABOLIC PARAMETERS OF
ANTIPSYCHOTIC CHILD TREATMENT
The
purpose of this study is to evaluate
the relative risks and benefits of
two approaches to the control of
weight gain and other negative side
effects in children and adolescents
on 2nd generation antipsychotics
(SGA):
•
Healthy
lifestyle instruction (nutritional
and physical activity surveillance
and advice) + continuation of current
SGA;
•
Add
the diabetes drug, metformin + continuation
of current SGA.
Ages:
10-17 |
| |
|
PREVENT-
METFORMIN MITIGATION OF ATYPICAL ANTIPSYCHOTIC-INDUCED
METABOLIC DYSREGULATION IN ADOLESCENT
YOUTHS
The
purpose of this study is to determine
whether starting
metformin in conjunction with a second-generation
antipsychotic (SGA) and providing
information about healthy eating and
activity will prevent or reduce
the amount of weight gain and
the metabolic changes typically seen
with second-generation antipsychotic
medication.
Ages:
10-17
|
|
|
|
|
back
to top »
|
